Found 8 hits for monomerid = 50144009 Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Glucagon receptor
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB MMDB
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| 63 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Abbott Laboratories
Curated by ChEMBL
| Assay Description In vitro binding affinity against human glucagon receptor (h-GlucR) was determined |
Bioorg Med Chem Lett 14: 2047-50 (2004)
Article DOI: 10.1016/j.bmcl.2004.02.056 BindingDB Entry DOI: 10.7270/Q2XS5TTH |
More data for this Ligand-Target Pair | |
Adenylate cyclase type 1/2/3/4/5/6/7/8/9
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB
UniProtKB/SwissProt
antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| 254 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Abbott Laboratories
Curated by ChEMBL
| Assay Description In vitro inhibitory activity against glucagon induced human adenylate cyclase |
Bioorg Med Chem Lett 14: 2047-50 (2004)
Article DOI: 10.1016/j.bmcl.2004.02.056 BindingDB Entry DOI: 10.7270/Q2XS5TTH |
More data for this Ligand-Target Pair | |
Glucagon receptor
(Rattus norvegicus) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 56 | n/a | n/a | n/a | n/a | n/a | n/a |
Novo Nordisk A/S
Curated by ChEMBL
| Assay Description Inhibition of rat glucagon receptor |
J Med Chem 50: 113-28 (2007)
Article DOI: 10.1021/jm058026u BindingDB Entry DOI: 10.7270/Q26M36GK |
More data for this Ligand-Target Pair | |
Gastric inhibitory polypeptide receptor
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Research Laboratories
Curated by ChEMBL
| Assay Description Antagonist activity at human GIPR expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation |
Bioorg Med Chem Lett 21: 76-81 (2010)
Article DOI: 10.1016/j.bmcl.2010.11.074 BindingDB Entry DOI: 10.7270/Q2R211PW |
More data for this Ligand-Target Pair | |
Glucagon receptor
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB MMDB
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 21 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Research Laboratories
Curated by ChEMBL
| Assay Description Displacement of [125I]glucagon from human GCGR expressed in CHO cells |
Bioorg Med Chem Lett 21: 76-81 (2010)
Article DOI: 10.1016/j.bmcl.2010.11.074 BindingDB Entry DOI: 10.7270/Q2R211PW |
More data for this Ligand-Target Pair | |
Glucagon receptor
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB MMDB
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 140 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Research Laboratories
Curated by ChEMBL
| Assay Description Antagonist activity at human GCGR expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation |
Bioorg Med Chem Lett 21: 76-81 (2010)
Article DOI: 10.1016/j.bmcl.2010.11.074 BindingDB Entry DOI: 10.7270/Q2R211PW |
More data for this Ligand-Target Pair | |
Glucagon-like peptide 1 receptor
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novo Nordisk A/S
Curated by ChEMBL
| Assay Description Inhibition of GLP1 receptor |
J Med Chem 50: 113-28 (2007)
Article DOI: 10.1021/jm058026u BindingDB Entry DOI: 10.7270/Q26M36GK |
More data for this Ligand-Target Pair | |
Glucagon receptor
(Homo sapiens (Human)) | BDBM50144009
(3-{4-[1-(4-tert-Butyl-cyclohexyl)-3-(4-trifluorome...)Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(Cc1ccc(cc1)C(=O)NCCC(O)=O)C(=O)Nc1ccc(OC(F)(F)F)cc1 |wU:4.3,wD:7.10,(10.18,2.9,;9.39,1.56,;8.05,2.34,;8.62,.21,;10.74,.78,;12.08,1.53,;13.41,.77,;13.41,-.77,;12.07,-1.54,;10.74,-.77,;14.74,-1.54,;14.74,-3.07,;13.39,-3.86,;12.07,-3.1,;10.74,-3.86,;10.74,-5.4,;12.07,-6.17,;13.41,-5.4,;9.41,-6.19,;9.43,-7.72,;8.06,-5.42,;6.74,-6.2,;5.4,-5.44,;4.07,-6.23,;2.73,-5.47,;4.07,-7.77,;16.06,-.77,;16.06,.77,;17.39,-1.54,;18.71,-.77,;20.04,-1.53,;21.38,-.77,;21.36,.78,;22.71,1.56,;22.7,3.09,;21.17,3.11,;24.23,3.11,;22.71,4.62,;20.04,1.55,;18.71,.77,)| Show InChI InChI=1S/C29H36F3N3O5/c1-28(2,3)21-8-12-23(13-9-21)35(27(39)34-22-10-14-24(15-11-22)40-29(30,31)32)18-19-4-6-20(7-5-19)26(38)33-17-16-25(36)37/h4-7,10-11,14-15,21,23H,8-9,12-13,16-18H2,1-3H3,(H,33,38)(H,34,39)(H,36,37)/t21-,23- | PDB MMDB
UniProtKB/SwissProt
B.MOAD antibodypedia GoogleScholar AffyNet
| Purchase
CHEMBL MCE PC cid PC sid UniChem
Patents
Similars
| Article PubMed
| n/a | n/a | 55 | n/a | n/a | n/a | n/a | n/a | n/a |
Novo Nordisk A/S
Curated by ChEMBL
| Assay Description Inhibition of human cloned glucagon receptor expressed in BHK cells |
J Med Chem 50: 113-28 (2007)
Article DOI: 10.1021/jm058026u BindingDB Entry DOI: 10.7270/Q26M36GK |
More data for this Ligand-Target Pair | |